New pill combo shows promise in slowing advanced breast cancer
NCT ID NCT05375461
First seen Apr 16, 2026 · Last updated Jun 13, 2026 · Updated 7 times
Summary
This study tested whether adding the experimental drug TQB3616 to standard hormone therapy (fulvestrant) can help slow cancer growth in people with a common type of advanced breast cancer (HR-positive, HER2-negative). About 293 women took part, receiving either the drug combo or a placebo plus fulvestrant. The main goal was to see how long the cancer stayed under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE,HER2-NEGATIVE IN ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hosptital
Beijing, Beijing Municipality, 100142, China
-
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, 100039, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.